NCT02419638View on ClinicalTrials.gov

Comparison of Rebif Compared to Tecifdera on Six-month Outcomes in Patients With Relapsing-remitting MS

WithdrawnOBSERVATIONAL
0
Timeline

Start Date

May 31, 2015

Primary Completion Date

December 31, 2015

Study Completion Date

February 29, 2016

Conditions
Multiple Sclerosis
Interventions
DRUG

Rebif (IFN β-1a subcutaneous three times per week)

DRUG

Tecifdera (dimethyl fumarate)

Trial Locations (1)

02445

Partners MS Center, 1 Brookline Place Suite 225, Brookline

Sponsors

Collaborators (1)

EMD Serono
All Listed Sponsors
collaborator

EMD Serono

INDUSTRY

lead

Brigham and Women's Hospital

OTHER

NCT02419638 - Comparison of Rebif Compared to Tecifdera on Six-month Outcomes in Patients With Relapsing-remitting MS | Biotech Hunter | Biotech Hunter